Read on Twitter
1/ $SRNGU I’ve been researching @Gingko most of the time I’ve been awake since the rumor from @Business broke yesterday.
This is the largest position I have ever held in a stock (my previous largest position was $CCIV at a $12 average).
This is the largest position I have ever held in a stock (my previous largest position was $CCIV at a $12 average).
2/ My play here is on the risk vs. reward that it presents. I do not anticipate $SRNGU doing anything like what $CCIV did.
3/ Ginko Bioworks is a very unique company in many regards. They are widely considered to be the market leader in synthetic biology. I encourage you to read about this industry on its own. It will be one of the most powerful forces on the planet for the duration of our lives.
4/ Ginkgo is incredibly unique in another way: they are a collection of spinoffs, investments and equity stakes in addition to its core business. My bet here is that $SRNGU is merging with the entire collection of equity. And I believe that to be incredibly valuable.
5/ Gingko is at once a play on marijuana ($MSOS, $CRON $CGC), COVID vaccines and testing, plant-based food ($BYND, $TTCF, $VRYYF), AgTech ( $APPH, $SV), 3D printing ($DM, $AONE, $DDD, $SPFR) as well as dozens of future industries.
6/ First, Ginko's core business. I believe we’re all aware the all of the technology in our lives - our computer, phones, televisions as well as the internet and websites are all written in code. The natural world of all living organisms is also written in code, that code is DNA.
7/ Ginko is creating “synthetic” DNA, meaning in a simplified way “new” or “man-made” DNA. By doing this, we can create almost anything from plants. Literally anything. Far off in the future, theoretically we could use this technology to grow a computer.
8/ What makes Ginkgo’s core business powerful is they doing for the emerging world of synbio what AWS does for websites. Ginkgo envisions a future where working with synthetic DNA and creating powerful organisms is as easy as building a new website.
9/ They are monetizing this by leveraging their position to take equity in many new synbio startups.
10/ "Ginkgo offers select start-ups access to its services in exchange for equity. The start-ups benefit from access to a technology stack that can save them large amounts of capital and time that would otherwise be sunk into building their own microbial design infrastructure."
12/ In addition to this core, Ginkgo has a strategy of creating new spin off companies and partnerships to disrupt industries as they see opportunities.
13/ Ginkgo created Motif Foodworks, a plant-based meat startup. Motif has attracted investments from Bill Gates, Jeff Bezos, Richard Branson and Jack Ma amongst others, through Breakthrough Energy. The only other SPACs Breakthrough has invested in are $QS and $DMYI.
14/ Gingko has partnered with Bayer, to create Joyn Bio, a company that aims to transform agriculture. Their first goal: eliminate the need for nitrogen fertilizers, which account for 3% of global emissions. They plan to do so by engineering dirt that can fertilize itself.
15/ They have partnered with Synlogic, which is working to make living medicines. "Both companies believe that the ability to program living cells to sense and respond to treat complex diseases has great potential, possibly transforming the next generation of pharmaceuticals.”
16/ They have partnered with $CRON to create lab grown cannabinoids.
"Cannabinoids span a range of molecules with different properties, and ongoing research has demonstrated potential medicinal uses for indications such as chronic pain, nervous disorders, nausea...
"Cannabinoids span a range of molecules with different properties, and ongoing research has demonstrated potential medicinal uses for indications such as chronic pain, nervous disorders, nausea...
17/ ..weight loss, and some mental illnesses. However, many pharmaceutically relevant cannabinoids are present only at very low quantities in the cannabis plant, making them economically impractical, difficult or impossible to extract at high purity and scale.”
18/ "The landmark partnership between Cronos Group and Ginkgo will leverage the expertise of both organizations to solve this challenge and make more accessible the benefits of cannabinoids in an economically sustainable way."
19/ They created another spinoff called Concentric which pools tests classrooms and schools for COVID. They have 800 schools signed up already and their revenue is $6 per student per week.
20/ At an average of 526 students per school, this alone is about $130 million of revenue per year. They’ll surely have many more schools signing up.
21/ In another new project, Ginkgo "produces the RNA all major mRNA Covid-19 vaccine manufacturers use in their doses”. https://investorplace.com/2021/04/srngu-stock-12-things-to-know-about-a-potential-ginkgo-bioworks-spac-merger/
